AP
ACAD
HealthcareAcadia Pharmaceuticals
Price Chart
Loading...
Market Data
Revenue TTMXBRL
—
Net IncomeXBRL
—
Gross MarginXBRL
—
EPS (Diluted)XBRL
—
No analysis generated yet. Run the pipeline for this company.
AI-extracted key facts from press releases and SEC filings. Significance 1–10.
4
OtherBullishPer-CompanyMar 25, 2026
Acadia Pharmaceuticals upgraded to Buy at Bank of America on attractive risk-reward profile
- ▸Bank of America upgraded ACAD to Buy from Neutral
- ▸Maintained $29 price target following 25% YTD stock pullback
- ▸Nuplazid peak sales modeled at $888M by 2029
- ▸Remlifanserin Phase 2 readout for Alzheimer's psychosis expected Aug-Oct
- ▸Commercial team expanded by 30% to drive Nuplazid growth